Small-Molecule Cancer Drug Revenues will Reach $32.7Bn in 2016

Tuesday 8 January 2013, Amsterdam

A new report by forecasts that small-molecule targeted cancer therapy revenues will reach $32.7bn worldwide in 2016. That drug market generated $21.7bn in 2011, according to Small-Molecule Targeted Cancer Therapies: World Market 2013-2023, published in December 2012.

This report forecasts that the overall market for small-molecule targeted cancer therapies will grow steadily to 2023. Rising disease prevalence, along with advances in pharmacotherapy and diagnostics, will stimulate that drug market. The R&D pipeline holds great promise. Also, in most countries, high demand exists for newer, better cancer treatments. There remain many commercial opportunities for small-molecule cancer treatments from 2013 to 2023, the study concludes.

Targeted cancer therapies block the growth and spread of cancer by interfering with molecules involved in tumour (tumor) growth and progression. Unlike antibody therapies, small-molecule targeted cancer drugs pass through cell membranes to reach targets inside cells.

Dr Syed Ahmed, a senior healthcare industry analyst in visiongain, said: “There remains a high unmet medical need for drugs that not only prolong patients’ survival but also significantly improve quality of life. Small-molecule targeted cancer agents will remain a prominent and lucrative part of the pharma market in the coming 10 years.

“The small-molecule targeted cancer therapy market continues to be dominated by blockbuster drugs led by Novartis’ Glivec (Gleevec). Many of the products are due to lose patent protection during our forecast period, 2013-2023, leaving significant opportunities for producers of generic drugs (generics). However, a robust R&D pipeline for small-molecule cancer therapies will ensure this segment remains dynamic and promising for innovator companies.”

Many small-molecule targeted technologies – including heat shock protein (HSP) modulators, HDAC mechanisms, transcription factor regulators and siRNA products – are in development for treating cancer. The R&D pipeline for those treatments is strong and vast, the report shows and discusses. Therapies are being studied for use alone, in combination with other targeted drugs, and combined with chemotherapy.

Much scope remains for medicines to combat growth, progression and spread of tumours. Visiongain’s report shows revenue forecasts to 2023 at overall world market, product and national level. The investigation predicts revenues of leading drugs, including Glivec (Gleevec), Revlimid, Alimta, Velcade and Tarceva. Research, data and analyses cover activities of Novartis, Eli Lilly, Roche, Pfizer, Takeda and other pharmaceutical companies.

The new study discusses R&D and commercial developments, shows research interviews and predicts overall revenues to 2023 in leading national markets. The work analyses the US, Japan, Germany, France, the UK, Spain, Italy (EU5), India and China.

Small-Molecule Targeted Cancer Therapies: World Market 2013-2023 adds to a range of analytical reports on industries and markets in healthcare.